FHND-71 is under clinical development by Protheragen and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how FHND-71’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

FHND-71 overview

FHND-71 is under development for the treatment of RET-driven solid tumors. The drug candidate acts by targeting tyrosine protein kinase receptor RET.

Protheragen overview

Protheragen discovers and develops therapies to treat cancers. The company is investing CD3XCD20 bsAb, an antibody therapy for the treatment of lymphomas; MUC1-Ab targeting acute myelocytic leukemia; LAG3-Ab and OX40-Ab to treat cancers; P75NEURO, against neurological diseases; P11 for the treatment of type 2 diabetes; and TT-173 against surgical bleeding and trauma. It is also developing therapies to treat nonalcoholic steatohepatitis, hepatitis B, epilepsy, Alzheimer’s disease and Psoriasis. Protheragen’s proprietary cyclic peptide information technology enables discovery of peptide therapeutics. The company provides project collection, transfer, collaboration and fundraising services. It operates in China. Protheragen is headquartered in New York, the US.

For a complete picture of FHND-71’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 18 March 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.